AcrySof Phakic IOL for Correction of Moderate-to-High Myopia: 1 Year Results

The implantation of a phakic intraocular lens (IOL) for the correction of moderate or high myopia has theoretical advantages in comparison with corneal procedures and clear lens extraction, such as precision and stability not dependent on the corneal healing process, a wider range of correction, magnification of the intraocular image, and preservation of accommodation. However, these lenses have also been associated with safety concerns such as uveitis, endophthalmitis, glaucoma, corneal damage, cataract, and pupil ovalization1-13. A new anterior chamber angle-supported phakic IOL, the AcrySof Cachet (Alcon Laboratories, Inc.), is single piece and composed of hydrophobic acrylate. Models of varying diameter are designed to fit within a variety of anterior chamber dimensions. Because it is foldable it can be inserted through a small corneal incision size (about 2.6 mm 3.0 mm) using the Monarch II IOL Delivery System («B» or «C» «P» cartridge). The haptics are designed to permit compression within the angle for IOL stability, without creating excessive force that could cause angle tissue damage or pupil ovalization. A previous multicenter clinical study has confirmed the good predictability, safety and efficacy of this ARTICLE